Light-to-moderate alcohol consumption may have protective health effects

Light-to-moderate drinking can lower risk of mortality from all-causes and cardiovascular disease, while heavy drinking can significantly increase risk of mortality from all-causes and cancer, according to a new study published today in the Journal of the American College of Cardiology. High alcohol consumption has been liked to a host of health issues, including cardiovascular disease, but alcohol in moderation is widely recommended. However, despite these recommendations, studies on the risk of mortality among light-to-moderate drinkers are inconsistent. Researchers in this study examined the association between alcohol consumption and risk of mortality from all causes, cancer and cardiovascular disease in the U.S.

The researchers looked at data from 333,247 participants obtained through the National Health Interview Surveys from 1997 to 2009. Study participants were surveyed regarding their alcohol consumption status and patterns of use. Alcohol consumption patterns were divided into six categories: lifetime abstainers, lifetime infrequent drinkers, former drinkers and current light (less than three drinks per week), moderate (more than three drinks per week to less than 14 drinks per week for men or less than seven drinks per week for women) or heavy drinkers (more than 14 drinks per week for men or seven drinks per week for women).

"Our research shows that light-to-moderate drinking might have some protective effects against cardiovascular disease, while heavy drinking can lead to death. A delicate balance exists between the beneficial and detrimental effects of alcohol consumption, which should be stressed to consumers and patients," said Bo Xi, MD, associate professor at the Shandong University School of Public Health in China and the study's lead author.

Throughout the length of the study, 34,754 participants died from all-causes. Of these, 8,947 mortalities were cardiovascular disease-specific (6,944 heart disease-related and 2,003 cerebrovascular-related deaths) and 8,427 mortalities were cancer-specific.

Researchers found that male heavy drinkers had a 25 percent increased risk of mortality due to all-causes and a 67 percent increase in mortality from cancer. These increases were not significantly noticed in women. There was no association found between heavy drinking and cardiovascular disease mortality. Moderate drinking was associated with a 13 percent and 25 percent decreased risk of all-cause mortality, and 21 percent and 34 percent decreased risk of cardiovascular disease mortality, respectively, in both men and women. Similar findings were observed for light drinking in both genders.

"We have taken rigorous statistical approaches to address issues reported in earlier studies such as abstainer bias, sick quitter phenomenon and limited confounding adjustment in our study. A J-shaped relationship exists between alcohol consumption and mortality, and drinkers should drink with consciousness," said one of the study's authors, Sreenivas Veeranki, MD, DrPH, assistant professor in preventive medicine and community health at University of Texas Medical Branch.

Limitations to the study include obtaining alcohol consumption status through survey responses that may be subject to recall bias, as well as using self-reported responses at baseline.

In an accompanying editorial, Giovanni de Gaetano, MD, PhD, director of the Department of Epidemiology and Prevention at IRCCS Istituto Neurologico Mediterraneo Neuromed said that while younger adults should not expect considerable benefit from moderate drinking, "for most older persons, the overall benefits of light drinking, especially the reduced cardiovascular disease risk, clearly outweigh possible cancer risk."

Bo Xi, Sreenivas P Veeranki, Min Zhao, Chuanwei Ma, Yinkun Yan, Jie Mi.
Relationship of Alcohol Consumption to All-Cause, Cardiovascular, and Cancer-Related Mortality in U.S. Adults.
Journal of the American College of Cardiology, Volume 70, Issue 8, Pages 913-922. doi: 10.1016/j.jacc.2017.06.054.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...